Skip to main content

Market Overview

Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock

Wedbush: Trajectory For Stemline Therapeutics' Blood Cancer Drug Priced Into Stock

Stemline Therapeutics Inc (NASDAQ: STML) reported a wider first-quarter net loss per share Friday, dragged by higher R&D expenses, which nearly tripled from a year ago.

The Analyst

Wedbush analyst David Nierengarten downgraded Stemline from Outperform to Neutral and maintained an $18 price target.

The Thesis

The positive launch trajectory of Elzonris and expectations for label expansion are priced into Stemline's stock, Nierengarten said in the Monday downgrade note. (See his track record here.) 

Elzonris, which is indicated for blastic plasmacytoid dendritic cell neoplasm — a rare, clinically aggressive form of blood cancer — was approved by the FDA in December and was made commercially available in January.

Elzonris sales in the first quarter were $5.05 million, ahead of Wedbush's estimate of $4.26 million.

Stemline said the treated patient pool included both recurring and treatment-naïve patients, with about 75 percent of them covered by Medicaid, the analyst said. 

Following the update, Wedbush modestly increased its 2019 sales estimate for Elzonris to $37.2 million.

Wedbush is looking ahead to additional Elzonris clinical updates in chronic myelomonocytic leukemia and myelofibrosis at the ASCO meeting scheduled for May 29-June 4, as well as a potential regulatory update regarding the indications following the company's planned registration discussions with the FDA in mid-2019.

With the MAA submitted in January, Elzonris could potentially be approved in Europe in the fourth quarter, Nierengarten said. 

Stemline is likely to have sufficient runway into 2021, with $86.1 million in net proceeds from the secondary offering in the first quarter as well as its existing cash and cash equivalent position of $124.4 million, according to Wedbush. 

The Price Action

Stemline shares have rallied by roughly 70 percent year-to-date. The stock was down 7.8 percent at $14.84 at the time of publication Monday. 

Related Links:

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report

Latest Ratings for STML

May 2020WedbushDowngradesOutperformNeutral
May 2020Ladenburg ThalmannDowngradesBuyNeutral
May 2020HC Wainwright & Co.DowngradesBuyNeutral

View More Analyst Ratings for STML
View the Latest Analyst Ratings


Related Articles (STML)

View Comments and Join the Discussion!

Posted-In: David Nierengarten WedbushAnalyst Color Downgrades Price Target Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

SBACJefferiesInitiates Coverage On335.0
SNCYWolfe ResearchInitiates Coverage On49.0
GWWMorgan StanleyMaintains427.0
GTESMorgan StanleyMaintains18.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at